S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
66,000% upside on tiny biotech? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
66,000% upside on tiny biotech? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
66,000% upside on tiny biotech? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
The single greatest medical breakthrough of all time? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
66,000% upside on tiny biotech? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:ADAG

Adagene (ADAG) Competitors

$1.25
-0.04 (-3.10%)
(As of 09/25/2023 ET)
Compare
Today's Range
$1.21
$1.31
50-Day Range
$1.14
$1.45
52-Week Range
$0.90
$2.10
Volume
7,097 shs
Average Volume
20,390 shs
Market Capitalization
$54.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

ADAG vs. ADCT, IMUX, EYEN, CLNN, SPRO, NERV, AEON, RMTI, VACC, and XLO

Should you be buying Adagene stock or one of its competitors? The main competitors of Adagene include ADC Therapeutics (ADCT), Immunic (IMUX), Eyenovia (EYEN), Clene (CLNN), Spero Therapeutics (SPRO), Minerva Neurosciences (NERV), AEON Biopharma (AEON), Rockwell Medical (RMTI), Vaccitech (VACC), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.

Adagene vs.

Adagene (NASDAQ:ADAG) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.

Adagene has a net margin of 0.00% compared to ADC Therapeutics' net margin of -98.33%. Adagene's return on equity of 0.00% beat ADC Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AdageneN/A N/A N/A
ADC Therapeutics -98.33%-325.79%-35.62%

Adagene has higher earnings, but lower revenue than ADC Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adagene$22.67M2.42-$79.97MN/AN/A
ADC Therapeutics$184.39M0.34-$155.80M-$2.27-0.36

Adagene presently has a consensus price target of $5.00, indicating a potential upside of 300.00%. ADC Therapeutics has a consensus price target of $8.20, indicating a potential upside of 914.22%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Adagene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adagene
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
ADC Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

ADC Therapeutics received 24 more outperform votes than Adagene when rated by MarketBeat users. However, 77.27% of users gave Adagene an outperform vote while only 60.29% of users gave ADC Therapeutics an outperform vote.

CompanyUnderperformOutperform
AdageneOutperform Votes
17
77.27%
Underperform Votes
5
22.73%
ADC TherapeuticsOutperform Votes
41
60.29%
Underperform Votes
27
39.71%

9.5% of Adagene shares are owned by institutional investors. Comparatively, 67.3% of ADC Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 35.4% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, ADC Therapeutics had 10 more articles in the media than Adagene. MarketBeat recorded 11 mentions for ADC Therapeutics and 1 mentions for Adagene. ADC Therapeutics' average media sentiment score of 0.32 beat Adagene's score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adagene
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ADC Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Adagene has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.

Summary

ADC Therapeutics beats Adagene on 9 of the 16 factors compared between the two stocks.


Get Adagene News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADAG vs. The Competition

MetricAdagenePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$56.55M$5.36B$4.39B$6.29B
Dividend YieldN/A2.74%5.90%9.76%
P/E RatioN/A7.91149.6113.67
Price / Sales2.42150.402,849.5556.56
Price / CashN/A19.4321.6822.67
Price / Book0.653.803.814.68
Net Income-$79.97M$180.15M$121.81M$185.66M
7 Day Performance-10.71%-3.51%-1.72%-2.09%
1 Month Performance3.75%-8.68%-3.32%-4.44%
1 Year Performance-5.30%7.25%9.59%6.02%

Adagene Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADCT
ADC Therapeutics
2.143 of 5 stars
$0.80
+2.6%
$7.67
+858.3%
-83.5%$61.45M$209.91M-0.35317Analyst Revision
Gap Down
IMUX
Immunic
1.8359 of 5 stars
$1.40
+1.5%
$5.00
+258.4%
-57.6%$62.22MN/A-0.4175Gap Down
EYEN
Eyenovia
2.1763 of 5 stars
$1.69
+3.0%
$12.00
+610.1%
-17.8%$62.67M$14M-2.4541Positive News
CLNN
Clene
2.4787 of 5 stars
$0.49
-9.3%
$7.50
+1,435.6%
-84.1%$62.71M$470,000.00-0.8075News Coverage
Gap Up
SPRO
Spero Therapeutics
2.4072 of 5 stars
$1.24
-0.8%
$7.50
+504.8%
-39.1%$65.90M$53.89M-4.7735
NERV
Minerva Neurosciences
2.1226 of 5 stars
$8.10
+2.5%
$11.00
+35.8%
-20.6%$56.62M$41.18M-1.639Positive News
AEON
AEON Biopharma
1.5209 of 5 stars
$6.30
-0.9%
$18.00
+185.7%
N/A$56.07MN/A0.009Gap Up
RMTI
Rockwell Medical
2.185 of 5 stars
$1.95
-3.0%
$11.00
+464.1%
+46.5%$55.56M$72.81M-2.22253Positive News
VACC
Vaccitech
2.0568 of 5 stars
$1.75
+2.3%
$12.00
+585.7%
+2.9%$67.43M$44.70M-1.2233Analyst Report
News Coverage
Gap Down
XLO
Xilio Therapeutics
2.0247 of 5 stars
$2.45
+2.1%
$11.25
+359.2%
-21.3%$67.47MN/A-0.8084Positive News
Gap Up

Related Companies and Tools

This page (NASDAQ:ADAG) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -